title: Pharmacokinetics of chlorogenic acid and corydaline in DA-9701, a new botanical gastroprokinetic agent, in rats.
abstract: 1.Few studies describing the pharmacokinetic properties of chlorogenic acid (CA) and corydaline (CRD) which are marker compounds of a new prokinetic botanical agent, DA-9701, have been reported. The aim of the present study is to evaluate the pharmacokinetic properties CA and CRD following intravenous and oral administration of pure CA (1-8 mg/kg) or CRD (1.1-4.5 mg/kg) and their equivalent dose of DA-9701 to rats. 2.  Dose-proportional AUC and dose-independent clearance (10.3-12.1 ml/min/kg) of CA were observed following its administration. Oral administration of CA as DA-9701 did not influence the oral pharmacokinetic parameters of CA. Incomplete absorption of CA, its decomposition in the gastrointestinal tract, and/or pre-systemic metabolism resulted in extremely low oral bioavailability (F) of CA (0.478-0.899%). 3.  CRD showed greater dose-normalized AUC in the higher dose group than that in lower dose group(s) after its administration due to saturation of its metabolism via decreased non-renal clearance (by 51.3%) and first-pass extraction. As a result, the F of CRD following 4.5 mg/kg oral CRD (21.1%) was considerably greater than those of the lower dose groups (9.10 and 13.8%). However, oral administration of CRD as DA-9701 showed linear pharmacokinetics as a result of increased AUC and F in lower-dose groups (by 182% and 78.5%, respectively) compared to those of pure CRD. The greater oral AUC of CRD for DA-9701 than for pure CRD could be due to decreased hepatic and/or GI first-pass extraction of CRD by other components in DA-9701.
authors.affiliation: College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea , Bucheon , South Korea and.
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Jung
authors.forename: Ju Myung
authors.initials: JM
authors.lastname: Kim
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Jeong
authors.forename: Miwon
authors.initials: M
authors.lastname: Son
authors.forename: Hye Suk
authors.initials: HS
authors.lastname: Lee
authors.forename: Myung Gull
authors.initials: MG
authors.lastname: Lee
authors.forename: Hee Eun
authors.initials: HE
authors.lastname: Kang
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001600:Berberine Alkaloids / Q000378:metabolism / Q000493:pharmacokinetics*; D001682:Biological Availability; D001798:Blood Proteins / Q000378:metabolism; D002726:Chlorogenic Acid / Q000378:metabolism / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D007275:Injections, Intravenous; D008297:Male; D028321:Plant Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017207:Rats, Sprague-Dawley
chemical_list: D001600:Berberine Alkaloids; D001798:Blood Proteins; C533973:DA-9701; D005765:Gastrointestinal Agents; D028321:Plant Preparations; C452799:corydaline; D002726:Chlorogenic Acid
keywords: Chlorogenic acid; DA-9701; corydaline; pharmacokinetics; rats